🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Italy / NCT07050693
Recruiting Not applicable

Efficacy of a 2'-Fucosylactose-based Food Supplement on the Prevention of Respiratory and Gastrointestinal Infections.

NCT07050693 · tracked via the Priya Life Science Italy tracker
Phase
Not applicable
Started
2025-04-17
Last updated
2025-07-09

Condition(s) studied

Gastroenteric TractRespiratory TractInfectionsGastroenteric Infections

Investigational drug(s) / intervention(s)

Vitamin + Zinc + micronutrient mixturePlacebo

Vitamin + Zinc + micronutrient mixture: a dietary supplement containing Vitamin D, Zinc, Beta glucan WELLMUNE WGP, 2'Fucosyllactose.

Placebo: Placebo is identical to intervention product

Study summary

Respiratory and gastrointestinal infections are frequent problems in children under 4 years of age, especially after the start of schooling. These conditions are facilitated by an incomplete maturation of the immune system and by the anatomical and functional structure of the respiratory and gastrointestinal tract still in development.

Functional foods derived from the fermentation of cow's milk with probiotic strains have been proposed for the prevention of infectious diseases in children. Several products have been investigated, sometimes with conflicting results. Some scientific evidence has shown that the administration of Vitamin D, Zinc, Beta glucan, 2'-Fucosyllactose can stimulate the immune defenses and reduce the number and severity of infectious episodes. In particular, 2'-fucosyllactose is one of the oligosaccharides of breast milk. It has both a prebiotic and immunoregulatory action since it is able to prevent the adhesion of pathogens to epithelial surfaces and subsequent translocation.

Healthy school-going children aged between 12 and 48 months, who attend school at least 5 days a week, will be evaluated.

Eligibility

Sex
ALL
Min age
12 Months
Max age
48 Months
Healthy volunteers
No
Inclusion Criteria: * Healthy school-going children aged 12 to 48 months who attend school at least 5 days a week Exclusion Criteria: * Age less than 12 months and more than 48 months; * Concomitant presence of chronic diseases * Congenital heart disease; * Tuberculosis; * Functional gastrointestinal disorders; * Gastrointestinal or urinary surgery of the respiratory tract; * Autoimmune diseases; * Immunodeficiencies; * Chronic inflammatory bowel diseases; * Celiac disease; * Cystic fibrosis; * Metabolic diseases; * Lactose intolerance; * Tumors; * Chronic lung diseases and malformations of the gastrointestinal tract; * Food allergies; * Eosinophilic esophagitis; * Other hypereosinophilic diseases of the gastrointestinal tract; * Diarrhea at enrollment; * Severe malnutrition (z score for weight/height less than 3SD); * Taking antibiotics and/or pre/pro/symbiotics/immunostimulants within 2 weeks of starting the study; * Breastfeeding in progress

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Pediatria Trambusti Bari Bari Recruiting

More University of Bari trials in Italy

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07050693 on ClinicalTrials.gov ↗ ← All trials in Italy